Last Updated: September 23, 2026

Cromolyn sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for cromolyn sodium and what is the scope of patent protection?

Cromolyn sodium is the generic ingredient in seven branded drugs marketed by King Pharms Llc, Sanofi Aventis Us, Ucb Inc, Ailex Pharms Llc, Genera Pharms, Micro Labs Ltd India, Rising, Viatris Specialty, Bausch And Lomb, Apotex Inc, Sandoz, Sciegen Pharms, King Pharms, Allergan, Actavis Mid Atlantic, Bausch, Eugia Pharma, Fera Pharms Llc, Hikma, Micro Labs, Roxane, Teva Pharms, Watson Labs, Wockhardt Bio Ag, Hh And P, Perrigo, and Blacksmith Brands, and is included in thirty-one NDAs. Additional information is available in the individual branded drug profile pages.

Eleven suppliers are listed for this compound.

Summary for cromolyn sodium
US Patents:0
Tradenames:7
Applicants:27
NDAs:31
Finished Product Suppliers / Packagers: 11
Raw Ingredient (Bulk) Api Vendors: 94
Clinical Trials: 23
Patent Applications: 7,129
What excipients (inactive ingredients) are in cromolyn sodium?cromolyn sodium excipients list
DailyMed Link:cromolyn sodium at DailyMed
Recent Clinical Trials for cromolyn sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Texas Tech University Health Sciences Center, El PasoPhase 3
Adli Karadsheh, MD, MSPhase 3
MedAvantePhase 2

See all cromolyn sodium clinical trials

Pharmacology for cromolyn sodium
Drug ClassMast Cell Stabilizer
Physiological EffectDecreased Histamine Release
Medical Subject Heading (MeSH) Categories for cromolyn sodium

US Patents and Regulatory Information for cromolyn sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Micro Labs CROMOLYN SODIUM cromolyn sodium SOLUTION;INHALATION 213658-001 Apr 29, 2022 AN RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hikma CROMOLYN SODIUM cromolyn sodium SOLUTION;INHALATION 075333-001 Apr 30, 2002 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sanofi Aventis Us INTAL cromolyn sodium CAPSULE;INHALATION 016990-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Perrigo CROMOLYN SODIUM cromolyn sodium SPRAY, METERED;NASAL 075427-001 Dec 12, 2001 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Wockhardt Bio Ag CROMOLYN SODIUM cromolyn sodium SOLUTION;INHALATION 075346-001 Oct 25, 1999 AN RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Bausch CROMOLYN SODIUM cromolyn sodium SOLUTION;INHALATION 075585-001 Dec 21, 2000 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for cromolyn sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc INTAL cromolyn sodium SOLUTION;INHALATION 018596-001 May 28, 1982 ⤷  Start Trial ⤷  Start Trial
Allergan OPTICROM cromolyn sodium SOLUTION/DROPS;OPHTHALMIC 018155-001 Oct 3, 1984 ⤷  Start Trial ⤷  Start Trial
King Pharms Llc INTAL cromolyn sodium AEROSOL, METERED;INHALATION 018887-001 Dec 5, 1985 ⤷  Start Trial ⤷  Start Trial
Sanofi Aventis Us INTAL cromolyn sodium CAPSULE;INHALATION 016990-001 Approved Prior to Jan 1, 1982 ⤷  Start Trial ⤷  Start Trial
Sanofi Aventis Us INTAL cromolyn sodium CAPSULE;INHALATION 016990-001 Approved Prior to Jan 1, 1982 ⤷  Start Trial ⤷  Start Trial
Sanofi Aventis Us INTAL cromolyn sodium CAPSULE;INHALATION 016990-001 Approved Prior to Jan 1, 1982 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.